



## **Provider Administered Drugs – Site of Care: Ocrevus® (Ocrelizumab)**

In the [May Network Bulletin](#), we communicated that Ocrevus® (ocrelizumab) was subject to site of care requirements. However, the revised Utilization Review Guideline titled *Provider Administered Drugs – Site of Care* inadvertently failed to list Ocrevus® (ocrelizumab). We have updated the policy to list Ocrevus® (ocrelizumab) and apologize for the inconvenience.

The updated policy is available at:

- Commercial Utilization Review Guideline: [Provider Administered Drugs – Site of Care](#)
- Oxford Clinical Policy: [Provider Administered Drugs – Site of Care](#)